64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients

[1]  J. Bading,et al.  Functional Imaging of Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET , 2014, The Journal of Nuclear Medicine.

[2]  Yasuyoshi Watanabe,et al.  64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer , 2013, The Journal of Nuclear Medicine.

[3]  A. Brufsky,et al.  Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. , 2013, Cancer treatment reviews.

[4]  N. Sneige,et al.  Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Balleine,et al.  HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis , 2011, Breast Cancer Research and Treatment.

[6]  K. Camphausen,et al.  Brain metastases as preventive and therapeutic targets , 2011, Nature Reviews Cancer.

[7]  M. Untch,et al.  Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. L. Jager,et al.  Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer , 2010, Clinical pharmacology and therapeutics.

[9]  Y. Nakasu,et al.  [Multidisciplinary management of brain metastases]. , 2010, Gan to kagaku ryoho. Cancer & chemotherapy.

[10]  M. Ono,et al.  Disruption of the blood brain barrier by brain metastases of triple‐negative and basal‐type breast cancer but not HER2/neu‐positive breast cancer , 2010, Cancer.

[11]  B. Leyland-Jones.  Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  John M S Bartlett,et al.  Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Ono,et al.  Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer , 2009, International Journal of Clinical Oncology.

[14]  M. Ono,et al.  Immunohistochemical profiles of brain metastases from breast cancer , 2008, Journal of Neuro-Oncology.

[15]  N. Harbeck,et al.  Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier , 2007, Anti-cancer drugs.

[16]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[17]  Terry L. Smith,et al.  Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Mohan Doss,et al.  Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. , 2005, Cancer research.

[19]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Cobleigh,et al.  Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Timmerman,et al.  Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J N Weinstein,et al.  A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  R K Jain,et al.  Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. , 1990, Cancer research.

[24]  J. Weinstein,et al.  The Pharmacology of Monoclonal Antibodies a , 1987, Annals of the New York Academy of Sciences.

[25]  S. Nakamura,et al.  Fc receptors of liver sinusoidal endothelium in normal rats and humans. A histologic study with soluble immune complexes. , 1987, Gastroenterology.

[26]  Satoshi Nakamura,et al.  Fc receptors of liver sinusoidal endothelium in normal rats and humans , 1987 .